866-997-4948(US-Canada Toll Free)

Oral Mucositis - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 91 Pages

Oral Mucositis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides an overview of the Oral Mucositis (Oncology) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Oral Mucositis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 2 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Oral Mucositis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Oncology).
- The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oral Mucositis (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oral Mucositis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Figures
Introduction
Global Markets Direct Report Coverage
Oral Mucositis - Overview
Oral Mucositis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Oral Mucositis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Oral Mucositis - Companies Involved in Therapeutics Development
Cellceutix Corp
Clevexel Pharma SA
Colby Pharmaceutical Company
Galera Therapeutics Inc
Humanetics Corp
Onxeo SA
Oragenics Inc
Otsuka Holdings Co Ltd
Soligenix Inc
Spectrum Pharmaceuticals Inc
Spherium Biomed SL
Oral Mucositis - Drug Profiles
AG-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCD-600 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clonidine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0095 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-4419 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SOD2 for Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HYLP-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-219 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pralatrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rebamipide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oral Mucositis - Dormant Projects
Oral Mucositis - Discontinued Products
Oral Mucositis - Product Development Milestones
Featured News & Press Releases
Jan 05, 2017: Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Dec 12, 2016: Soligenix Announces SGX942 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
Dec 08, 2016: Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis
Dec 08, 2016: Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Nov 21, 2016: U.S. FDA Grants Fast Track Designation for the Development of Oragenics AG013 for Oral Mucositis
Oct 26, 2016: Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications
Oct 18, 2016: Soligenix Announces Publication of its Phase 2 Clinical Trial Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Sep 27, 2016: Galera Therapeutics Announces Presentation of One-Year Follow-up Data from a Phase 1b/2a Study of GC4419 In the Reduction of Severe Oral Mucositis
Sep 06, 2016: Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs
Aug 30, 2016: Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment
Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference
Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis
May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol
Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Oral Mucositis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Oral Mucositis - Pipeline by Cellceutix Corp, H1 2017
Oral Mucositis - Pipeline by Clevexel Pharma SA, H1 2017
Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H1 2017
Oral Mucositis - Pipeline by Galera Therapeutics Inc, H1 2017
Oral Mucositis - Pipeline by Humanetics Corp, H1 2017
Oral Mucositis - Pipeline by Onxeo SA, H1 2017
Oral Mucositis - Pipeline by Oragenics Inc, H1 2017
Oral Mucositis - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Oral Mucositis - Pipeline by Soligenix Inc, H1 2017
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
Oral Mucositis - Pipeline by Spherium Biomed SL, H1 2017
Oral Mucositis - Dormant Projects, H1 2017
Oral Mucositis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Oral Mucositis - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Oral Mucositis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *